Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.
Administration, Oral
Aged
Atrial Fibrillation
/ drug therapy
Dabigatran
/ standards
Factor Xa Inhibitors
/ standards
Female
Humans
Italy
Male
Middle Aged
Pyrazoles
/ standards
Pyridones
/ standards
Registries
/ statistics & numerical data
Renal Insufficiency, Chronic
/ complications
Rivaroxaban
/ standards
Statistics, Nonparametric
Treatment Outcome
Chronic kidney disease
Direct oral anticoagulant
Non-valvular atrial fibrillation
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
15
03
2019
accepted:
29
04
2019
pubmed:
11
5
2019
medline:
6
5
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
Patients with non-valvular atrial fibrillation (NVAF) and chronic kidney disease (CKD) are at increased risk of stroke and bleeding. Although direct oral anticoagulant (DOAC) trials excluded patients with severe CKD, a growing portion of CKD patients have been starting DOACs and limited data from real-world outcome in this high-risk setting are available. The INSigHT registry included 632 consecutive NVAF patients that started apixaban (256 patients, 41%), dabigatran (245, 39%) and rivaroxaban (131, 20%) between 2012 and 2015. Based on creatinine clearance, two sub-cohorts were defined: (1) non-CKD group (CrCl 60-89 mL/min, 413 patients) and (2) CKD group (15-59 ml/min, 219). Compared to non-CKD patients, those with CKD, were at higher ischemic (CHA
Identifiants
pubmed: 31073827
doi: 10.1007/s11739-019-02100-9
pii: 10.1007/s11739-019-02100-9
doi:
Substances chimiques
Factor Xa Inhibitors
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Rivaroxaban
9NDF7JZ4M3
Dabigatran
I0VM4M70GC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1259-1270Commentaires et corrections
Type : CommentIn
Références
J Am Heart Assoc. 2012 Aug;1(4):e002097
pubmed: 23130165
Int J Cardiol. 2017 Jun 1;236:363-369
pubmed: 28131705
J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82
pubmed: 25500231
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Kidney Int. 2011 Jul;80(2):181-9
pubmed: 21389969
Eur Heart J. 2017 Jul 14;38(27):2137-2149
pubmed: 27282612
Eur Heart J. 2015 Feb 1;36(5):297-306
pubmed: 24722803
Thromb Haemost. 2015 Jun;113(6):1247-57
pubmed: 25739533
Ann Rheum Dis. 2015 Feb;74(2):323-5
pubmed: 25261576
BMJ. 2017 Feb 10;356:j510
pubmed: 28188243
Int J Cardiol. 2017 Mar 15;231:162-169
pubmed: 28007305
N Engl J Med. 2012 Aug 16;367(7):625-35
pubmed: 22894575
Eur Heart J. 2017 Mar 21;38(12):860-868
pubmed: 26848150
Clin Res Cardiol. 2015 May;104(5):418-29
pubmed: 25416564
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Cardiol Rev. 2006 Jan-Feb;14(1):14-7
pubmed: 16371761
Circulation. 2009 Mar 17;119(10):1363-9
pubmed: 19255343
J Am Coll Cardiol. 2016 Jun 21;67(24):2888-99
pubmed: 27311528
Eur Heart J. 2016 Apr 7;37(14):1145-53
pubmed: 26330425
J Am Soc Nephrol. 2009 Apr;20(4):912-21
pubmed: 19225037
J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93
pubmed: 26065986
Am Heart J. 2018 Apr;198:166-168
pubmed: 29653639
Thromb Haemost. 2013 Aug;110(2):205-12
pubmed: 23702623
J Am Soc Nephrol. 2009 Apr;20(4):705-11
pubmed: 19092127
Circulation. 2014 Mar 4;129(9):961-70
pubmed: 24323795
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Circulation. 2016 Jul 5;134(1):37-47
pubmed: 27358435
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36
pubmed: 27680880
J Thromb Haemost. 2010 Jan;8(1):202-4
pubmed: 19878532
Intern Emerg Med. 2017 Apr;12(3):387-406
pubmed: 28191610
Intern Emerg Med. 2018 Oct;13(7):1069-1075
pubmed: 29956065
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Can J Cardiol. 2014 Aug;30(8):888-97
pubmed: 25064581
Nephron Clin Pract. 2010;115(2):c142-6
pubmed: 20413993
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
PLoS One. 2014 Aug 01;9(8):e101245
pubmed: 25084117
Eur Heart J. 2012 Nov;33(22):2821-30
pubmed: 22933567
Eur Heart J. 2011 Oct;32(19):2387-94
pubmed: 21873708
BMJ Open. 2018 Jan 24;8(1):e019638
pubmed: 29371284